995 related articles for article (PubMed ID: 28434148)
1. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Ren J; Zhao Y
Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
3. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
[TBL] [Abstract][Full Text] [Related]
4. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
5. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
Li C; Mei H; Hu Y
Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
[TBL] [Abstract][Full Text] [Related]
6. Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system.
Hajifathali A; Lasemi MV; Mehravar M; Moshari MR; Alizadeh AM; Roshandel E
Hematol Transfus Cell Ther; 2024; 46(1):58-66. PubMed ID: 37451978
[TBL] [Abstract][Full Text] [Related]
7. Retroviral Vectors for Cancer Gene Therapy.
Schambach A; Morgan M
Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
[TBL] [Abstract][Full Text] [Related]
8. Engineering T Cells Using CRISPR/Cas9 for Cancer Therapy.
Zhang X; Cheng C; Sun W; Wang H
Methods Mol Biol; 2020; 2115():419-433. PubMed ID: 32006414
[TBL] [Abstract][Full Text] [Related]
9. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
Liu X; Zhao Y
Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
Ghaffari S; Khalili N; Rezaei N
J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic applications of CRISPR RNA-guided genome editing.
Koo T; Kim JS
Brief Funct Genomics; 2017 Jan; 16(1):38-45. PubMed ID: 27562951
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
14. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
15. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
Doetschman T; Georgieva T
Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
[TBL] [Abstract][Full Text] [Related]
16. Emerging CRISPR/Cas9 applications for T-cell gene editing.
Preece R; Georgiadis C
Emerg Top Life Sci; 2019 May; 3(3):261-275. PubMed ID: 33523139
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More.
Ou X; Ma Q; Yin W; Ma X; He Z
Front Cell Dev Biol; 2021; 9():674467. PubMed ID: 34095145
[TBL] [Abstract][Full Text] [Related]
18. Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects.
Georgiadis C; Preece R; Nickolay L; Etuk A; Petrova A; Ladon D; Danyi A; Humphryes-Kirilov N; Ajetunmobi A; Kim D; Kim JS; Qasim W
Mol Ther; 2018 May; 26(5):1215-1227. PubMed ID: 29605708
[TBL] [Abstract][Full Text] [Related]
19. Application of Genome Editing Techniques in Immunology.
Zych AO; Bajor M; Zagozdzon R
Arch Immunol Ther Exp (Warsz); 2018 Aug; 66(4):289-298. PubMed ID: 29344676
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic gene editing in haematological disorders with CRISPR/Cas9.
Jensen TI; Axelgaard E; Bak RO
Br J Haematol; 2019 Jun; 185(5):821-835. PubMed ID: 30864164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
